Neisseria Meningitidis Meningitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for neisseria meningitidis meningitis. 10 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
10
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered

Originators in Neisseria Meningitidis Meningitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 10 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating neisseria meningitidis meningitis. Each bar = one year. Y-axis scaled to peak year (7 patents).

7
31
1
38
2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Merrem
Meropenem
 Pfizer 10 57 — 2031-08-08

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12478606 Merrem method of use 75 2038-01-08
12533342 Merrem method of use 75 2039-05-20
11376237 Merrem method of use 70 2039-04-06
11007206 Merrem method of use 68 2031-08-08
9694025 Merrem method of use 68 2031-08-08
10561675 Merrem method of use 68 2031-08-08
10183034 Merrem method of use 68 2031-08-08
10172874 Merrem formulation 48 2031-08-08
12171772 Merrem composition of matter 23 2031-08-08
8680136 Merrem composition of matter 10 2031-08-29

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8680136 Merrem composition of matter 10 2031-08-29
12171772 Merrem composition of matter 23 2031-08-08
10172874 Merrem formulation 48 2031-08-08
9694025 Merrem method of use 68 2031-08-08
10183034 Merrem method of use 68 2031-08-08
11007206 Merrem method of use 68 2031-08-08
10561675 Merrem method of use 68 2031-08-08
11376237 Merrem method of use 70 2039-04-06
12533342 Merrem method of use 75 2039-05-20
12478606 Merrem method of use 75 2038-01-08

Related